| | |
Univariate analysis
| |
Multivariate analysis
| |
|---|
|
Factors
|
N (%)
|
OR
|
95% IC
|
p value
|
OR
|
95% IC
|
p value
|
|---|
|
PS at MAHA diagnosis
|
|
PS 1–2
|
30 (55.6%)
|
1.0
| |
0.003
|
1.0
| |
0.01
|
|
PS 3–4
|
24 (44.4%)
|
6.0
|
[1.8; 19.8]
| |
7.0
|
[1.6; 31.8]
| |
|
Clinical bleeding
|
|
Yes
|
9 (16.7%)
|
NS
| | |
NS
| | |
|
No
|
45 (83.3%)
| | | | | | |
|
Neurological symptoms
|
|
Yes
|
15 (28.3%)
|
NS
| | |
NS
| | |
|
No
|
38 (71.7%)
| | | | | | |
|
NA
|
1
| | | | | | |
|
Dyspnoea
|
|
Yes
|
11 (20.8%)
|
NS
| | |
NS
| | |
|
No
|
42 (79.2%)
| | | | | | |
|
NA
|
1
| | | | | | |
|
Metastatic sites
|
|
< 3
|
25 (46.3%)
|
NS
| | |
NS
| | |
|
≥ 3
|
29 (53.7%)
| | | | | | |
|
Metastasis
|
|
Bone marrowa
|
11 (78.5%)
| | | | | | |
|
Bone
|
44 (81.5%)
| | | | | | |
|
Lung
|
8 (14.8%)
|
NS
| | |
NS
| | |
|
Liver
|
35 (64.8%)
| | | | | | |
|
Otherb
|
24 (44.4%)
| | | | | | |
|
Number of prior treatment lines
|
|
≤ 1
|
26 (48.1%)
|
1.0
| |
0.06
|
NS
| | |
|
> 1
|
28 (51.9%)
|
2.9
|
[1.0; 8.7]
| | | | |
|
Platelets
|
|
< 50 G/L
|
29 (53.7%)
|
NS
| | |
NS
| | |
|
≥ 50 G/L
|
25 (46.3%)
| | | | | | |
|
Haemoglobin
|
|
< 8 g/L
|
26 (48.1%)
|
4.0
|
[1.3; 12.5]
|
0.02
|
3.7
|
[0.9; 16.7]
|
0.08
|
|
≥ 8 g/L
|
28 (51.9%)
|
1.0
| | |
1.0
| | |
|
Schistocytes
|
|
> 5.0%
|
10 (25.0%)
|
NS
| | |
NS
| | |
|
0.5–5.0%
|
30 (75.0%)
| | | | | | |
|
NA
|
14
| | | | | | |
|
Erythroblastemia
|
|
Yes
|
40 (85.1%)
|
NS
| | |
NS
| | |
|
No
|
7 (14.9%)
| | | | | | |
|
NA
|
7
| | | | | | |
|
Myelemia
|
|
Yes
|
38 (90.5%)
|
NS
| | |
NS
| | |
|
No
|
4 (9.5%)
| | | | | | |
|
NA
|
12
| | | | | | |
|
Prothrombin time
|
|
< 50%
|
8 (16.0%)
|
4.5
|
[0.9; 25.0]
|
0.07
|
9.1
|
[1.2; 50.0]
|
0.03
|
|
≥ 50%
|
42 (84.0%)
|
1.0
| | |
1.0
| | |
|
NA
|
4
| | | | | | |
|
Fibrinogen
|
|
≤ 2 g/L
|
15 (34.9)
|
NS
| | |
NS
| | |
|
> 2 g/L
|
28 (65.1)
| | | | | | |
|
NA
|
11
| | | | | | |
|
Glomerular filtration eate
|
|
> 60 mL/min
|
25 (65.8%)
|
NS
| | |
NS
| | |
|
30–60 mL/min
|
9 (23.7%)
|
NS
| | | | | |
|
< 30 mL/min
|
4 (10.5%)
|
NS
| | | | | |
|
NA
|
16
| | | | | | |
|
Total bilirubin level
|
|
< 1.24 mg/dL
|
16 (30.8%)
|
1.0
| |
0.007
|
1.0
| | |
|
≥ 1.24 mg/dL
|
36 (69.2%)
|
7.3
|
[1.8; 30.6]
| |
6.9
|
[1.1; 42.6]
|
0.04
|
|
NA
|
2
| | | | | | |
|
Pronopall scorec
|
|
Short survival
|
12 (31.6%)
|
3.7
|
[0.8; 16.8]
|
0.09
| | | |
|
Intermediate/long survival
|
26 (68.4%)
|
1.0
| | |
NS
| | |
|
NA
|
16
| | | | | | |
- NA not available, OR odds ratio, NS non-significant
- aOnly 14 patients had a bone marrow examination (myelogram or bone marrow biopsy) at the time of BC-MAHA diagnosis
- bOthers metastatic sites: cerebral, carcinomatous meningitis, node involvement
- cThe pronopall score for early death among oncology patients was calculated according to Barbot et al., J Clin Oncol 2008, missing data being imputed
